Compound Evidence File
#EC-2026-0056
PMK methyl glycidate CAS 1369021-80-6
Filed under Raw Materials. The bureau holds 108 laboratory returns for this compound from 37 distinct subjects. Scores below are per-subject aggregates; open a subject row for the underlying evidence.
Cross-Index
Subjects Shipping This Compound
37 SUBJECTS| Subject | Grade | Samples | Mean | Min | Max | First seen | Last seen |
|---|---|---|---|---|---|---|---|
| Tianjin Finder Chemical TFCCASE #VI-2026-0693 | A | 6 | 10.0 | 9.9 | 10.0 | 14 Nov 2025 | 16 Apr 2026 |
| Shanghai ERP BiotechnologyCASE #VI-2026-0936 | A | 4 | 10.0 | 9.9 | 10.0 | 7 Jan 2026 | 27 Jun 2026 |
| Mokemei BiotechnologyCASE #VI-2026-0540 | A | 4 | 10.0 | 9.9 | 10.0 | 4 Jan 2026 | 24 Jun 2026 |
| Hybio PharmaceuticalCASE #VI-2026-0065 | A | 4 | 10.0 | 9.9 | 10.0 | 8 Feb 2026 | 6 Aug 2026 |
| QYAOBIOCASE #VI-2026-0861 | A | 3 | 10.0 | 9.9 | 10.0 | 9 Dec 2025 | 3 Jun 2026 |
| Kerui PeptidesCASE #VI-2026-0626 | A | 3 | 10.0 | 10.0 | 10.0 | 16 Dec 2025 | 25 May 2026 |
| WuXi TIDESCASE #VI-2026-0335 | A | 3 | 10.0 | 9.9 | 10.0 | 4 May 2026 | 27 May 2026 |
| AsymchemCASE #VI-2026-0091 | A | 3 | 10.0 | 9.9 | 10.0 | 10 Dec 2025 | 26 Apr 2026 |
| Sangon BioCASE #VI-2026-0671 | A | 2 | 10.0 | 10.0 | 10.0 | 22 Dec 2025 | 8 May 2026 |
| Shanghai Wibson BiotechnologyCASE #VI-2026-0379 | A | 2 | 10.0 | 10.0 | 10.0 | 12 May 2026 | 20 May 2026 |
| PolyPeptide GroupCASE #VI-2026-0143 | A | 2 | 10.0 | 10.0 | 10.0 | 2 Feb 2026 | 9 Jul 2026 |
| Kits4lessCASE #VI-2026-0744 | X | 1 | 10.0 | 10.0 | 10.0 | 16 Mar 2025 | 16 Mar 2025 |
| HomopeptideCASE #VI-2026-0760 | A | 6 | 9.9 | 9.9 | 10.0 | 24 May 2026 | 24 May 2026 |
| Hubei JianxiangCASE #VI-2026-0048 | A | 4 | 9.9 | 9.9 | 10.0 | 14 Jan 2026 | 14 May 2026 |
| Chinese Peptide CompanyCASE #VI-2026-0184 | A | 4 | 9.9 | 9.9 | 10.0 | 19 Feb 2026 | 4 Jul 2026 |
| Shanghai Sigma AudleyCASE #VI-2026-0505 | A | 4 | 9.9 | 9.9 | 10.0 | 13 Nov 2025 | 19 Apr 2026 |
| JEEP PeptidesCASE #VI-2026-0457 | A | 3 | 9.9 | 9.9 | 10.0 | 18 May 2026 | 6 Jul 2026 |
| BachemCASE #VI-2026-0314 | A | 3 | 9.9 | 9.9 | 10.0 | 25 Feb 2026 | 7 Apr 2026 |
| Sigma-AldrichCASE #VI-2026-0829 | A | 3 | 9.9 | 9.9 | 10.0 | 2 Jul 2026 | 9 Jul 2026 |
| AmbioPharmCASE #VI-2026-0177 | A | 3 | 9.9 | 9.9 | 10.0 | 18 Mar 2026 | 20 Jun 2026 |
| Flourishglobal PeptideCASE #VI-2026-0630 | A | 2 | 9.9 | 9.9 | 9.9 | 22 Mar 2026 | 24 Jun 2026 |
| GenScript PeptidesCASE #VI-2026-0860 | A | 2 | 9.9 | 9.9 | 9.9 | 14 Mar 2026 | 2 Jun 2026 |
| Thermo Fisher ScientificCASE #VI-2026-0142 | A | 2 | 9.9 | 9.9 | 10.0 | 14 Feb 2026 | 20 Jun 2026 |
| SinoPepCASE #VI-2026-0387 | A | 2 | 9.9 | 9.9 | 10.0 | 16 Jun 2026 | 13 Aug 2026 |
| Wuhan Wansheng Bio (WWB)CASE #VI-2026-0594 | A | 5 | 9.3 | 7.9 | 10.0 | 23 May 2026 | 23 May 2026 |
| Risynth BioCASE #VI-2026-0672 | X | 1 | 9.3 | 9.3 | 9.3 | 16 Mar 2025 | 16 Mar 2025 |
| Shanghai Sigma Audley SSACASE #VI-2026-0486 | A | 6 | 9.0 | 8.3 | 10.0 | 21 May 2026 | 21 May 2026 |
| Nantong Guangyuan Chemical GYCCASE #VI-2026-0284 | A | 2 | 8.9 | 8.9 | 8.9 | 24 May 2026 | 24 May 2026 |
| Glbiochem (Shanghai)CASE #VI-2026-0704 | A | 5 | 8.4 | 7.9 | 9.6 | 21 May 2026 | 21 May 2026 |
| Forever Young PharmacyCASE #VI-2026-0654 | X | 1 | 8.4 | 8.4 | 8.4 | 6 May 2025 | 6 May 2025 |
| Qingdao Sigma Chemical QSCCASE #VI-2026-0538 | A | 2 | 8.1 | 7.9 | 8.2 | 24 May 2026 | 24 May 2026 |
| Royal PeptidesCASE #VI-2026-0264 | X | 2 | 7.3 | 6.0 | 8.7 | 8 Jul 2025 | 24 May 2026 |
| Peptide SciencesCASE #VI-2026-0867 | X | 5 | 6.5 | 4.8 | 8.0 | 13 Feb 2025 | 20 May 2026 |
| Pharma Grade PeptidesCASE #VI-2026-0208 | X | 1 | 5.4 | 5.4 | 5.4 | 21 May 2025 | 21 May 2025 |
| WllyBIOCASE #VI-2026-0470 | X | 1 | 2.5 | 2.5 | 2.5 | 24 Apr 2025 | 24 Apr 2025 |
| Coffee and PeppersCASE #VI-2026-0274 | X | 1 | 0.4 | 0.4 | 0.4 | 6 May 2025 | 6 May 2025 |
| Marvel PeptideCASE #VI-2026-0507 | X | 1 | 0.0 | 0.0 | 0.0 | 28 Mar 2025 | 28 Mar 2025 |
Open any subject to view the batch-level evidence for PMK methyl glycidate CAS 1369021-80-6 alone.